Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial

Summary: Background: Recent evidence indicates a potential therapeutic role of fluvoxamine for COVID-19. In the TOGETHER trial for acutely symptomatic patients with COVID-19, we aimed to assess the efficacy of fluvoxamine versus placebo in preventing hospitalisation defined as either retention in a...

Descripció completa

Dades bibliogràfiques

Autors principals:	Gilmar Reis, PhD, Eduardo Augusto dos Santos Moreira-Silva, PhD, Daniela Carla Medeiros Silva, PhD, Lehana Thabane, ProfPhD, Aline Cruz Milagres, RN, Thiago Santiago Ferreira, MD, Castilho Vitor Quirino dos Santos, Vitoria Helena de Souza Campos, Ana Maria Ribeiro Nogueira, MD, Ana Paula Figueiredo Guimaraes de Almeida, MD, Eduardo Diniz Callegari, MD, Adhemar Dias de Figueiredo Neto, PhD, Leonardo Cançado Monteiro Savassi, PhD, Maria Izabel Campos Simplicio, BScPharm, Luciene Barra Ribeiro, RN, Rosemary Oliveira, Ofir Harari, PhD, Jamie I Forrest, MPH, Hinda Ruton, MSc, Sheila Sprague, PhD, Paula McKay, MSc, Alla V Glushchenko, MD, Craig R Rayner, FRCPE, Eric J Lenze, ProfMD, Angela M Reiersen, MD, Gordon H Guyatt, ProfMD, Edward J Mills, ProfFRCP
Format:	Artigo
Idioma:	Inglês
Publicat:	Elsevier 2022-01-01
Col·lecció:	The Lancet Global Health
Accés en línia:	http://www.sciencedirect.com/science/article/pii/S2214109X21004484
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!